The eradication of smallpox was officially declared by the WHO in 1980, leading to
discontinuation of the vaccination campaign against the virus. Consequently, immunity …

Two decades after a worldwide vaccination campaign was used to successfully eradicate
naturally occurring smallpox, the threat of bioterrorism has led to renewed vaccination …

Vaccinia virus (VACV) L1 is an important target for viral neutralization and has been
included in multicomponent DNA or protein vaccines against orthopoxviruses. To further …

Orthopoxviruses such as variola and monkeypox viruses continue to threaten the human
population. Monkeypox virus is endemic in central and western Africa and outbreaks have …

Concerns about infections caused by orthopoxviruses, such as variola and monkeypox
viruses, drive ongoing efforts to develop novel smallpox vaccines that are both effective and …

The possible reemergence of smallpox through bioterrorism requires the preparation of
adequate stockpiles of vaccine. Dryvax, the only US-licensed vaccinia virus smallpox …

Recombinant proteins are being evaluated as smallpox and monkeypox vaccines because
of their perceived safety compared to live vaccinia virus. Previously, we demonstrated that …

Since the global eradication of smallpox in the 1980s, monkeypox has become the most
severe infectious disease caused by pathogenic orthopoxvirus (OPXV) infection. Monkeypox …

Concerns about bioterrorism and outbreaks of zoonotic orthopoxvirus require safe and
efficacious smallpox vaccines. We previously reported the clinical efficacy and safety profiles …

Smallpox (variola virus) is a bioweapon concern. Monkeypox is a growing zoonotic poxvirus
threat. These problems have resulted in extensive efforts to develop potential therapeutics …